Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25944898 | 0.85 | GCGR (0.33) | EIF4A3METAP2 | |
| SCHEMBL15417382 | 0.84 | EIF4A3 (0.35) | EIF4A3PDE2AACE2TRPA1LMNA | |
| SCHEMBL20622503 | 0.83 | EIF4A3 (0.40) | EIF4A3PDE2AACE2FEN1 | |
| SCHEMBL27342165 | 0.82 | GABRA1 (0.35) | EIF4A3TRPA1LMNACHRM1SLC6A2 | |
| SCHEMBL20226998 | 0.78 | EIF4A3 (0.34) | EIF4A3ACE2METAP2 | |
| SCHEMBL24319896 | 0.78 | LMNA (0.38) | EIF4A3TRPA1LMNACHRM1SLC6A2 | |
| SCHEMBL9621393 | 0.74 | GABRA1 (0.31) | — | |
| SCHEMBL12599604 | 0.74 | LMNA (0.35) | EIF4A3PDE2ATRPA1LMNACHRM1 | |
| SCHEMBL15247293 | 0.74 | LMNA (0.40) | EIF4A3TRPA1LMNACHRM1SLC6A2 | |
| SCHEMBL8097082 | 0.74 | RIPK1 (0.38) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131356-A1 | PREPARATION OF PROTECTED ALPHA-KETO BETA-AMINO ESTERS AND AMIDES | VERTEX PHAMACEUTICALS INCORPORATED (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131356-A1 | PREPARATION OF PROTECTED ALPHA-KETO BETA-AMINO ESTERS AND AMIDES | BCKDK, PTMS, DNPEP | EIF4A3 3841/4885PDE2A 3873/4885ACE2 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.